Researchers Identify Possible Cause of Chronic Pain in Parkinson’s Patients
source: pixabay.com

Researchers Identify Possible Cause of Chronic Pain in Parkinson’s Patients

Chronic pain affects about two-thirds of those with Parkinson's, making it the major non-motor symptom of the disease. A study published in Movements Disorders has found that anandamide and glucocerebroside…

Continue Reading Researchers Identify Possible Cause of Chronic Pain in Parkinson’s Patients
ICYMI: Recurrent Respiratory Papillomatosis Treatment Receives Orphan Drug Designation
source: pixabay.com

ICYMI: Recurrent Respiratory Papillomatosis Treatment Receives Orphan Drug Designation

INO-3107, a treatment for recurrent respiratory papillomatosis (RRP), has recently received the Orphan Drug Designation from the FDA. This treatment is currently being evaluate in a Phase 1/2 trial by…

Continue Reading ICYMI: Recurrent Respiratory Papillomatosis Treatment Receives Orphan Drug Designation
This Criteria Helps Predict Chronic Kidney Disease in Lupus Nephritis Patients
source: pixabay.com

This Criteria Helps Predict Chronic Kidney Disease in Lupus Nephritis Patients

Lupus nephritis causes kidney inflammation and can often lead to chronic kidney disease (CKD). An issue that medical professionals have faced is predicting the likelihood of individual patients developing CKD.…

Continue Reading This Criteria Helps Predict Chronic Kidney Disease in Lupus Nephritis Patients
ICYMI: Levodopa Intestinal Gel as a Treatment for Off Periods in Parkinson’s Disease
source: pixabay.com

ICYMI: Levodopa Intestinal Gel as a Treatment for Off Periods in Parkinson’s Disease

According to Parkinson's News Today, an intestinal gel comprised of levodopa and carbidopa (LCIG) is able to lower the amount of time that Parkinson's patients spend in off episodes. These…

Continue Reading ICYMI: Levodopa Intestinal Gel as a Treatment for Off Periods in Parkinson’s Disease
New Drug Application for Niemann-Pick Disease Type C Treatment
source: pixabay.com

New Drug Application for Niemann-Pick Disease Type C Treatment

Orphazyme has recently submitted their New Drug Application to the FDA for their Niemann-Pick disease type C (NPC) treatment, arimoclomol. This application comes after the biopharmaceutical company was already granted…

Continue Reading New Drug Application for Niemann-Pick Disease Type C Treatment
Ankylosing Spondylitis Treatment Approved but Not Yet Available
https://pixabay.com/en/approved-pass-ok-approval-symbol-1726357/

Ankylosing Spondylitis Treatment Approved but Not Yet Available

According to Ankylosing Spondylitis News, a new treatment, Hulio, has been approved by the FDA. It is a treatment for ankylosing spondylitis and other inflammatory disorders. Although it has been…

Continue Reading Ankylosing Spondylitis Treatment Approved but Not Yet Available
Possible New Treatment for Facioscapulohumeral Muscular Dystrophy
source: pixabay.com

Possible New Treatment for Facioscapulohumeral Muscular Dystrophy

A team of researchers from the University of Alberta have created a possible treatment for facioscapulohumeral muscular dystrophy (FSHD). Their work has been published in the Proceedings of the National Academy…

Continue Reading Possible New Treatment for Facioscapulohumeral Muscular Dystrophy
Close Menu